Study Evaluating Orally Administered Moxidectin In Subjects With Onchocerca Volvulus Infection

• ClinicalTrials.gov Identifier: NCT00300768
• Recruitment Status: Completed
• First Posted: March 9, 2006
• Last Update Posted: December 15, 2022
• Sponsor: Medicines Development for Global Health
• Collaborator: World Health Organization
• Information provided by (Responsible Party): Medicines Development for Global Health

Study Description

Brief Summary:

The primary purpose of this study was to determine the safety and tolerability of moxidectin in subjects infected with Onchocerca volvulus (a parasitic worm).

Condition or disease	Intervention/treatment	Phase
Onchocerciasis	Drug: 2 mg moxidectin; Drug: ivermectin 150 mcg/kg; Drug: 4 mg moxidectin; Drug: 8 mg moxidectin	Phase 2

Detailed Description:

This was a phase 2, randomized, ivermectin-controlled, double-blind, single-ascending-dose, parallel design, inpatient/outpatient study of moxidectin administered to subjects of both sexes with different degrees of severity of O. volvulus infection. The study was conducted at a single site in Ghana.

Secondary objects are to determine the pharmacokinetics of moxidectin, to obtain initial indication of the efficacy in terms of long term effect on skin microfilaria levels and an indication of the effect on the macrofilaria that may underlie the effect on skin microfilaria levels.

Subjects were enrolled in consecutive cohorts to receive a single oral dose of 2 mg, 4 mg or 8 mg or moxidectin or ivermectin 150 µg/kg by severity of infection, based on the mean of the skin microfilariae densities at each of 4 body locations, both iliac crests and calves.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 172 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: A Randomized, Single-Ascending Dose, Ivermectin-Controlled, Double-Blind, Safety, Tolerability, Pharmacokinetic, and Efficacy Study Of Orally Administered Moxidectin In Subjects With Onchocerca Volvulus Infection
• Actual Study Start Date: September 6, 2006
• Actual Primary Completion Date: November 2009
• Actual Study Completion Date: November 29, 2009

Arms and Interventions

Arm	Intervention/treatment
Experimental: 2 mg moxidectin; 2 mg moxidectin (Dose-escalation 1st step)	Drug: 2 mg moxidectin; Single-dose, tablet encapsulated for blinding
Active Comparator: Ivermectin 150 mcg/kg; Active comparator arm (ivermectin 150 mcg/kg).	Drug: ivermectin 150 mcg/kg; Single-dose, tablets encapsulated for blinding
Experimental: 4 mg moxidectin; 4 mg moxidectin (dose escalation second step)	Drug: 4 mg moxidectin; Single dose, tablets encapsulated for blinding
Experimental: 8 mg moxidectin; 8 mg moxidectin (dose escalation third step)	Drug: 8 mg moxidectin; single dose, tablets encapsulated for blinding

Outcome Measures

Primary Outcome Measures :

1. Incidence of clinical adverse events and clinically significant laboratory test results [ Time Frame: Duration of follow up (18 months) ]

Secondary Outcome Measures :

1. Skin mf counts at day 8 and months 1, 2, 3, 6, 12 and 18 [ Time Frame: day 8 and months 1, 2, 3, 6, 12, 18 ]
2. Nodulectomy at 18 months [ Time Frame: 18 months ]
3. Pharmacokinetics (PKs) at days 1, 2, 4, 13, and 18 and months 1, 2, 3, 6 and 12 [ Time Frame: days 1, 2, 4, 13, and 18 and months 1, 2, 3, 6 and 12 ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 60 Years (Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Written, signed (or thumb-printed), and dated informed consent
2. Aged 18 to 60 years, inclusive
3. Body weight ≥ 40 kg for women and ≥ 45 kg for men
4. Nonpregnant, nonbreastfeeding women. Women of child bearing potential must agree to use birth control during the first 150 days after treatment.
5. Healthy, as determined by a physician on the basis of a physical examination, ECG, and a thorough review of the medical history and clinical laboratory results
6. Adequate hematologic, renal, and hepatic function
7. Skin microfilarial density within the required range for the cohort

Exclusion Criteria:

1. Participation in any studies other than purely observational ones, within 4 weeks before test article administration.
2. Any vaccination within 4 weeks before test article administration
3. Acute infection requiring therapy within the last 10 days before test article administration
4. Administration of any medication (with the exception of medication required to treat any reactions during the screening fluorescein angiography (chlorpheniramine) or paracetamol) or herbal preparation within 10 days prior to test article administration or any condition currently requiring regular medication
5. Clinically significant ECG abnormalities or history of cardiac abnormality
6. Past or current history of neurological or neuropsychiatric disease or epilepsy
7. Subjects with orthostatic hypotension at the screening evaluation
8. History of drug or alcohol abuse or regular use of ≥ 3 cigarettes per day
9. Use of alcohol or other drugs of abuse within 72 hours before test article administration
10. Any condition, in the investigator's opinion, that places the subject at undue risk
11. Subjects who have donated blood within 8 weeks before study entry
12. Subjects with ocular onchocerciasis in cohorts intended to enroll subjects with mild infection. Ocular onchocerciasis is defined by the presence of live or dead microfilariae, onchocercal punctate opacities, onchocercal lesions of the posterior segment or lesions that mimic those seen in onchocerciasis.
13. Subjects with hyperreactive onchodermatitis
14. Antifilarial therapy within the previous 5 years
15. Coincidental infection with Loa Loa
16. Female subjects of childbearing potential with a contraindication to DMPA if not on Norplant
17. Any other condition which the investigator feels would exclude the subject from the study

Contacts and Locations

Locations

Ghana

Onchocerciasis Chemotherapy Research Center

Hohoe, Volta Region, Ghana

Sponsors and Collaborators

Medicines Development for Global Health

World Health Organization

Investigators

• Principal Investigator: Nicholas Opoku, MD; Onchocerciasis Chemotherapy Research Center, Hohoe, Ghana

More Information

Additional Information:

Awadzi et al 2014 

Publications of Results:

Awadzi K, Opoku NO, Attah SK, Lazdins-Helds J, Kuesel AC. A randomized, single-ascending-dose, ivermectin-controlled, double-blind study of moxidectin in Onchocerca volvulus infection. PLoS Negl Trop Dis. 2014 Jun 26;8(6):e2953. doi: 10.1371/journal.pntd.0002953. eCollection 2014 Jun.

• Responsible Party: Medicines Development for Global Health
• ClinicalTrials.gov Identifier: NCT00300768
• Other Study ID Numbers: 3110A1-200-GH; B1751004 ( Other Identifier: Protocol ID: Pfizer ); OCRC 33 ( Other Identifier: Protocol ID: WHO, OCRC )
• First Posted: March 9, 2006
• Last Update Posted: December 15, 2022
• Last Verified: November 2022

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: No

Keywords provided by Medicines Development for Global Health:

onchocerciasis; onchocerca volvulus; river blindness; ivermectin; moxidectin

Additional relevant MeSH terms:

Onchocerciasis; Intestinal Volvulus; Infections; Filariasis; Spirurida Infections; Secernentea Infections; Nematode Infections; Helminthiasis; Parasitic Diseases; Skin Diseases, Parasitic; Skin Diseases, Infectious; Skin Diseases; Intestinal Obstruction; Intestinal Diseases; Gastrointestinal Diseases; Digestive System Diseases; Torsion Abnormality; Pathological Conditions, Anatomical; Ivermectin; Moxidectin; Antiparasitic Agents; Anti-Infective Agents; Anthelmintics; Antinematodal Agents